Beigene Ltd
NASDAQ:BGNE

  • LAST PRICE
    187.6900
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    140.0000/ 1
  • Ask / Lots
    209.6800/ 1
  • Open / Previous Close
    --- / 187.6900
  • Day Range
    ---
  • 52 Week Range
    126.9681
    248.1600
  • Volume
    347

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
BGNE
Beigene Ltd
20.7B
-22.8x
---
UTHR
United Therapeutics Corp
16.0B
15.8x
+8.22%
BMRN
BioMarin Pharmaceutical Inc
11.8B
37.2x
---
EXAS
Exact Sciences Corp
9.2B
-42.3x
---
NBIX
Neurocrine Biosciences Inc
11.9B
31.5x
+62.04%
INCY
Incyte Corp
14.8B
550.0x
+39.11%
As of 2024-11-19

Company Information

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Contact Information

Headquarters
C/O Mourant Governance Services (Cayman) 94 Solaris Avenue, Camana BayGRAND CAYMAN, BEJ, Cayman Islands KY1-1108
Phone
345-949-4123
Fax
---

Executives

Co-Founder, Executive Chairman of the Board, Chief Executive Officer
John Oyler
President, Chief Operating Officer, General Manager - China
Xiaobin Wu
Co-Founder, Non-Executive Director
Xiaodong Wang
Chief Financial Officer
Aaron Rosenberg
Senior Vice President, General Counsel
Chan Lee

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$20.7B
Revenue (TTM)
$3.3B
Shares Outstanding
106.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.56
EPS
$-8.24
Book Value
$36.95
P/E Ratio
-22.8x
Price/Sales (TTM)
6.2
Price/Cash Flow (TTM)
---
Operating Margin
-26.31%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.